Gyre Therapeutics Inc (GYRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 105,757 | 113,450 | 102,290 | 7,338 | 20,948 |
| Cost of Goods | 3,884 | 4,636 | 4,793 | 7,380 | 9,163 |
| Gross Profit | 101,873 | 108,814 | 97,497 | -42 | 11,785 |
| Operating Expenses | 86,594 | 176,680 | 89,087 | 88,232 | 69,318 |
| Operating Income | 16,163 | -67,230 | 9,203 | -87,894 | -57,370 |
| Other Income | 7,055 | -9,735 | 209 | -39 | 1,129 |
| Pre-tax Income | 23,218 | -76,965 | 9,412 | -87,933 | -56,241 |
| Income Tax | 5,320 | 8,515 | 5,098 | N/A | N/A |
| Net Income Continuous | 17,898 | -85,480 | 4,314 | -87,933 | -56,241 |
| Minority Interests | 5,813 | 7,453 | 2,012 | N/A | N/A |
| Net Income | $12,085 | $-92,933 | $2,302 | $-87,933 | $-56,241 |
| EPS Basic Total Ops | 0.14 | -1.41 | 0.04 | -43.03 | -43.93 |
| EPS Basic Continuous Ops | 0.21 | -1.30 | 0.07 | -43.03 | -43.96 |
| EPS Diluted Total Ops | 0.05 | -1.41 | 0.03 | -43.03 | -43.93 |
| EPS Diluted Continuous Ops | 0.18 | -1.30 | 0.06 | -43.03 | -43.96 |
| EPS Diluted Before Non-Recurring Items | 0.10 | 0.27 | -31.18 | -43.03 | -43.93 |
| EBITDA(a) | $17,751 | $-66,116 | $10,332 | $-87,604 | $-57,232 |